The medtech industry is
going through some fundamental transformation. This is especially true when it
comes to pricing pressure and the companies’ dilemma on how best to use R&D
capital. Paul LaViolette, managing partner and chief operating officer of SV
Life Sciences Advisers explained "I used to spend 9% of sales on R&D.
I can’t do that anymore because I am investing in growth drivers that are not
technology related, so I am reducing my R&D as a percentage of sales".
He also realized that companies are using some of the R&D budget on
maintaining market leadership in areas they already excel in.
And the next big medtech
trend is related to it: "If you look at the big outsourcing trends over
the last 10 years, it was contract manufacturing. I think the big trend in the
next 10 years is going to be contract development”. Now, contract development
companies developed engineering talent that is as good as what large companies
have. LaViolette added that going the contract development route is also cost
effective for medtech companies.
"Why should I hire
20 FTEs (full-time equivalents), put them on my benefits program, my retirement
program, everything else when I can contract that out if I have faith that the
contracted strategy can deliver the same benefit?” he asked rhetorically.
"If it works out well, it can be part of my long term franchise strategy.
Then I'll hire internal resources to support it."
However, LaViolette made
it clear that “contract development allows companies to share the risk of
developing new programs where they don't have the engineering skill sets
internally.” Medtech companies are not going to do that if they are already the
market leader.
Grandes informações! Excelente escrita. Tenho certeza de que vai visitar este site novamente em breve.
ReplyDeleteEu tenho algumas informações relevantes você pode rever abaixo
liftderma Ingrendientes
liftderma experiências